Dori Thomas-Karyat
Company: Synthis
Job title: Chief Executive Officer
Seminars:
Defeating the Highly Potent Toxicity of ADCs Targeting TGF-β for Effective Patient Response 9:00 am
Evolving the ALK5 inhibitor payload to achieve patient treatment success Targeting TGF-β receptors using ADC to avoid toxicity in the heart and bone Avoiding systematic toxicity in TGF-β directed therapies by highly specific targeting for better patient responseRead more
day: Conference Day Two
Fireside Chat: Assessing the TGF-β Landscape & Predicting Future Innovations 9:30 am
Exploring the current clinical successes of TGF-β targeted therapies Discussing the changes in the TGF-β field with the pivot to fibrosis research Looking to the future for developing TGF-β directed therapies and exciting new technologies using TGF-βRead more
day: Conference Day One